SillaJen’s BAL0891, a first-in-class dual-targeting oncology drug, was licensed by Swiss biotech company Basilea Pharmaceutica Ltd. in 2021. To assess the synergy between BAL0891 and immune checkpoint ...

Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Receiving Palbociclib ... other ...

WASHINGTON (AP) — U.S. regulators have approved the first cervical cancer testing kit that allows women to collect their own sample at home before shipping it to a laboratory, according to a ...

WHAT ARE SOME OF THE SIGNS AND SYMPTOMS WOMEN SHOULD BE AWARE OF? WELL, UNFORTUNATELY, EARLY STAGE CERVICAL CANCER WHEN IT FIRST PRESENTS IS OFTEN ASYMPTOMATIC OR DOESN’T HAVE SYMPTOMS.